Connect Biopharma Holdings Past Earnings Performance
Past criteria checks 0/6
Connect Biopharma Holdings has been growing earnings at an average annual rate of 21.1%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 162% per year.
Key information
21.1%
Earnings growth rate
41.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 162.0% |
| Return on equity | -19.4% |
| Net Margin | -88.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Connect Biopharma Holdings (NASDAQ:CNTB) Is In A Strong Position To Grow Its Business
Sep 27
Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Are In A Position To Invest In Growth
Mar 07Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Invest In Growth?
Sep 19Will Connect Biopharma Holdings (NASDAQ:CNTB) Spend Its Cash Wisely?
Mar 29Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Deliver On Growth Plans?
Dec 14Market Appears To Relegate Connect Biopharma To A Long-Term Hold
Oct 10Connect Biopharma Is A Sleeper Heading Into October Data Readout
Sep 26Connect Biopharma reports 1H results
Sep 13We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate
Aug 12We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate
Apr 29Connect Biopharma's Latest Dermatitis Drug Update Fails To Pump Up Shares
Jan 12We're Hopeful That Connect Biopharma Holdings (NASDAQ:CNTB) Will Use Its Cash Wisely
Jan 01Revenue & Expenses Breakdown
How Connect Biopharma Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 24 | -21 | 14 | 39 |
| 31 Mar 24 | 12 | -40 | 14 | 45 |
| 31 Dec 23 | 0 | -60 | 15 | 52 |
| 30 Sep 23 | 0 | -77 | 17 | 64 |
| 30 Jun 23 | 0 | -93 | 19 | 76 |
| 31 Mar 23 | 0 | -104 | 20 | 85 |
| 31 Dec 22 | 0 | -118 | 21 | 97 |
| 30 Sep 22 | 0 | -131 | 22 | 101 |
| 30 Jun 22 | 0 | -114 | 22 | 96 |
| 31 Mar 22 | 0 | -163 | 21 | 91 |
| 01 Jan 22 | 0 | -202 | 19 | 80 |
| 30 Sep 21 | 0 | -229 | 16 | 64 |
| 30 Jun 21 | 0 | -255 | 14 | 48 |
| 31 Mar 21 | 0 | -185 | 10 | 35 |
| 31 Dec 20 | 0 | -119 | 7 | 23 |
| 31 Dec 19 | 0 | -24 | 1 | 15 |
Quality Earnings: CNTB is currently unprofitable.
Growing Profit Margin: CNTB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CNTB is unprofitable, but has reduced losses over the past 5 years at a rate of 21.1% per year.
Accelerating Growth: Unable to compare CNTB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CNTB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: CNTB has a negative Return on Equity (-19.35%), as it is currently unprofitable.